Forest Ray

The order is part of a settlement between the two companies and follows a preliminary injunction that the same court granted Natera in December of last year.

Following a lung cancer study, the firm plans to initiate similar studies in other cancers and to launch a new tumor profiling assay later this year.

Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.

The nonprofit behind the work aims to bring the test to market in the next 18 to 24 months and is in discussions with potential commercialization partners. 

Patients will be offered germline genetic testing after an assessment that includes genetic, lifestyle, and other clinical risk factor analysis.

The epigenetic risk stratification test demonstrated the potential to decrease surveillance among some patients and increase it among others.

The Medical Genetic Multiomics Laboratory recently launched its first diagnostic test, a whole-transcriptome RNA-seq assay, commercialized by Baylor Genetics.

Natera's total revenue grew 58 percent year over year, driven by strong growth in total tests processed and in oncology test volume.

The biomarker p-tau 217 best correlated with other established signs of Alzheimer's disease in a head-to-head study evaluating six blood-based assays.

The company's Q2 revenues rose to $92.3 million from $70.3 million the year before, beating the consensus Wall Street estimate of $67.9 million.